PriceTargets.com logo

Veru - VERU Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $33.50
  • Forecasted Upside: 519.22%
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$5.41 As of 02/7/2023 01:00 AM ET
▼ -0.3 (-5.25%)

This chart shows the closing price for VERU by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Veru Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for VERU and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for VERU

Analyst Price Target is $33.50
▲ +519.22% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Veru in the last 3 months. The average price target is $33.50, with a high forecast of $55.00 and a low forecast of $18.00. The average price target represents a 519.22% upside from the last price of $5.41.

This chart shows the closing price for VERU for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 5 contributing investment analysts is to buy stock in Veru. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/16/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/14/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/12/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/13/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/11/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/9/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/8/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/7/2023

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/7/2022HC WainwrightLower TargetBuy$21.00 ➝ $18.00Low
11/10/2022HC WainwrightLower TargetBuy$24.00 ➝ $21.00Low
8/11/2022Cantor FitzgeraldBoost Target$24.00 ➝ $30.00Low
5/18/2022Brookline Capital AcquisitionBoost TargetBuy ➝ Buy$29.00 ➝ $31.00Medium
5/18/2022Brookline Capital ManagementBoost TargetBuy ➝ Buy$29.00 ➝ $31.00Medium
5/13/2022Cantor FitzgeraldReiterated RatingOverweightHigh
5/13/2022Jefferies Financial GroupBoost Target$33.00 ➝ $55.00High
4/12/2022OppenheimerBoost TargetOutperform$25.00 ➝ $36.00High
4/12/2022HC WainwrightBoost TargetBuy$21.00 ➝ $24.00High
1/11/2022HC WainwrightReiterated RatingBuy$21.00High
12/3/2021HC WainwrightReiterated RatingBuy$20.00High
10/14/2021HC WainwrightReiterated RatingBuy$21.00High
9/21/2021HC WainwrightReiterated RatingBuy$21.00Low
8/27/2021Brookline Capital ManagementReiterated RatingBuyMedium
8/27/2021OppenheimerReiterated RatingBuy$26.00High
6/28/2021HC WainwrightReiterated RatingBuy$21.00High
4/13/2021Jefferies Financial GroupInitiated CoverageBuy$19.00High
2/25/2021HC WainwrightLower TargetBuy$22.00 ➝ $21.00High
2/11/2021OppenheimerBoost Target$19.00 ➝ $24.00Low
2/9/2021HC WainwrightBoost TargetBuy$12.00 ➝ $17.00Low
12/16/2020OppenheimerBoost TargetOutperform$9.00 ➝ $19.00Low
12/14/2020Brookline Capital ManagementBoost Target$13.00 ➝ $17.00High
12/14/2020Cantor FitzgeraldBoost TargetOverweight$6.00 ➝ $15.00High
12/10/2020HC WainwrightBoost TargetBuy$6.00 ➝ $8.00High
9/21/2020OppenheimerReiterated RatingBuy$9.00High
8/14/2020Brookline Capital ManagementReiterated RatingBuyLow
8/14/2020OppenheimerReiterated RatingBuy$9.00High
6/22/2020HC WainwrightReiterated RatingBuy$6.00High
5/14/2020OppenheimerBoost TargetOutperform$9.00Medium
5/6/2020HC WainwrightReiterated RatingBuy$6.00Low
1/21/2020HC WainwrightReiterated RatingBuy ➝ Buy$4.50 ➝ $6.00High
12/13/2019HC WainwrightReiterated RatingBuy$4.50High
10/3/2019HC WainwrightReiterated RatingBuyLow
8/9/2019HC WainwrightReiterated RatingBuy$4.50High
7/29/2019Brookline Capital ManagementInitiated CoverageBuy$12.00High
7/1/2019Cantor FitzgeraldInitiated CoverageOverweight$6.00High
6/27/2019HC WainwrightReiterated RatingBuy$4.50Medium
6/5/2019HC WainwrightSet TargetBuy$5.00Medium
3/20/2019CIBCInitiated CoverageOutperform ➝ Outperform$5.00High
3/19/2019OppenheimerInitiated CoverageOutperform$5.00 ➝ $5.00High
2/14/2019Maxim GroupSet TargetBuy$6.00Medium
1/23/2019HC WainwrightReiterated RatingBuy$4.50Low
12/14/2018HC WainwrightSet TargetBuy$5.00Low
9/13/2018HC WainwrightSet TargetBuy$5.00Medium
8/28/2018HC WainwrightSet TargetBuy$5.00Low
8/27/2018Maxim GroupReiterated RatingBuy$10.00High
8/15/2018HC WainwrightReiterated RatingBuy$5.00Medium
8/14/2018Maxim GroupReiterated RatingBuy$10.00Low
7/3/2018Maxim GroupInitiated CoverageBuyHigh
6/25/2018Dawson JamesReiterated RatingBuyMedium
5/18/2018HC WainwrightSet TargetBuy$5.00Low
5/10/2018HC WainwrightSet TargetBuy$5.00Low
3/23/2018HC WainwrightSet TargetBuy$5.00High
3/6/2018HC WainwrightSet TargetBuy$5.00High
2/15/2018HC WainwrightSet TargetBuy$5.00Low
(Data available from 2/7/2018 forward)

News Sentiment Rating

1.08 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 8 very positive mentions
  • 25 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
7/12/2022
  • 3 very positive mentions
  • 16 positive mentions
  • 3 negative mentions
  • 4 very negative mentions
Mentions as of
8/11/2022
  • 5 very positive mentions
  • 44 positive mentions
  • 4 negative mentions
  • 8 very negative mentions
Mentions as of
9/10/2022
  • 6 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 5 very negative mentions
Mentions as of
10/10/2022
  • 2 very positive mentions
  • 8 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
Mentions as of
11/9/2022
  • 8 very positive mentions
  • 4 positive mentions
  • 3 negative mentions
  • 7 very negative mentions
Mentions as of
12/9/2022
  • 1 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
1/8/2023
  • 4 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/7/2023

Current Sentiment

  • 4 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Veru logo
Veru, Inc. is an oncology biopharmaceutical company, which engages in developing novel medicines for the management of prostate cancer and breast cancer. Its prostate cancer drug candidates include: VERU-111, an oral alpha and beta tubulin inhibitor, which is in a Phase 2 clinical trial for the treatment of metastatic castration and androgen receptor targeting agent resistant prostate cancer, VERU-100, a novel, proprietary, GnRH antagonist peptide drug formulation designed to address the current limitations of commercially available androgen deprivation therapies (ADT) for advanced prostate cancer, and Zuclomiphene Citrate, an oral nonsteroidal estrogen receptor agonist being developed to treat hot flashes, a common side effect caused by ADT. The firm's breast cancer drug candidates include: Enobosarm, an oral, new chemical entity, selective androgen receptor agonist that targets the androgen receptor in AR+/ER+/HER2-hormone sensitive metastatic breast cancer without unwanted virilizing side effects, and VERU 111 for triple negative metastatic breast cancer that has become resistant to taxane IV chemotherapy. It is also advancing the new drug formulation TADFYN, tadalafil and fin
Read More

Today's Range

Now: $5.41
Low: $5.22
High: $5.78

50 Day Range

MA: $5.58
Low: $4.78
High: $6.41

52 Week Range

Now: $5.41
Low: $4.34
High: $24.55

Volume

2,065,695 shs

Average Volume

1,756,111 shs

Market Capitalization

$436.15 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Veru?

The following Wall Street sell-side analysts have issued research reports on Veru in the last twelve months: Brookline Capital Acquisition Corp., Brookline Capital Management, Cantor Fitzgerald, HC Wainwright, Jefferies Financial Group Inc., Oppenheimer Holdings Inc., and TheStreet.
View the latest analyst ratings for VERU.

What is the current price target for Veru?

6 Wall Street analysts have set twelve-month price targets for Veru in the last year. Their average twelve-month price target is $33.50, suggesting a possible upside of 527.3%. Jefferies Financial Group Inc. has the highest price target set, predicting VERU will reach $55.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $18.00 for Veru in the next year.
View the latest price targets for VERU.

What is the current consensus analyst rating for Veru?

Veru currently has 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe VERU will outperform the market and that investors should add to their positions of Veru.
View the latest ratings for VERU.

What other companies compete with Veru?

Other companies that are similar to Veru include Nature's Sunshine Products, Kezar Life Sciences, Esperion Therapeutics, Silence Therapeutics and Phathom Pharmaceuticals. Learn More about companies similar to Veru.

How do I contact Veru's investor relations team?

Veru's physical mailing address is 48 NW 25th Street Suite 102, Miami FL, 33127. The company's listed phone number is (305) 509-6897 and its investor relations email address is [email protected] The official website for Veru is www.veruhealthcare.com. Learn More about contacing Veru investor relations.